CN102178704A - 以红豆杉精油和红豆杉提取物为原料的消炎药 - Google Patents
以红豆杉精油和红豆杉提取物为原料的消炎药 Download PDFInfo
- Publication number
- CN102178704A CN102178704A CN2011100946039A CN201110094603A CN102178704A CN 102178704 A CN102178704 A CN 102178704A CN 2011100946039 A CN2011100946039 A CN 2011100946039A CN 201110094603 A CN201110094603 A CN 201110094603A CN 102178704 A CN102178704 A CN 102178704A
- Authority
- CN
- China
- Prior art keywords
- ramulus
- folium taxi
- taxi cuspidatae
- extract
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title abstract description 6
- 241001149649 Taxus wallichiana var. chinensis Species 0.000 title abstract 6
- 239000002260 anti-inflammatory agent Substances 0.000 title description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 25
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000006260 foam Substances 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 4
- 239000012141 concentrate Substances 0.000 claims abstract description 3
- 238000000053 physical method Methods 0.000 claims abstract description 3
- 239000000839 emulsion Substances 0.000 claims abstract 3
- 239000003921 oil Substances 0.000 claims description 21
- 235000019198 oils Nutrition 0.000 claims description 21
- 206010061218 Inflammation Diseases 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 13
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 210000004994 reproductive system Anatomy 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 208000006374 Uterine Cervicitis Diseases 0.000 claims description 3
- 206010046914 Vaginal infection Diseases 0.000 claims description 3
- 201000008100 Vaginitis Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 206010008323 cervicitis Diseases 0.000 claims description 3
- 230000003628 erosive effect Effects 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 201000003265 lymphadenitis Diseases 0.000 claims description 3
- 208000004396 mastitis Diseases 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 230000007234 antiinflammatory process Effects 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- -1 make oral suspensoid Substances 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 3
- 239000008157 edible vegetable oil Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 241001116500 Taxus Species 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 230000003467 diminishing effect Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000009977 dual effect Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 210000004996 female reproductive system Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000019476 oil-water mixture Nutrition 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000271 synthetic detergent Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种经过物理方法提取所得的红豆杉精油和红豆杉提取物制成的具有消炎、抗癌双重功效的药品。该红豆杉精油和红豆杉提取物直接应用于制药工业生产的适合口服或外用的消炎、抗癌制剂，如：胶囊剂、乳剂、混悬剂、粉剂、泡沫剂等。
Description
技术领域
本发明涉及把红豆杉提取物和红豆杉精油应用消炎杀菌领域，同时通过消炎杀菌时的应用，利用红豆杉提取物和红豆杉精油抗癌的作用，在消炎杀菌的过程中起到预防癌症的作用。
背景技术
众所周知，红豆杉提取物中紫杉醇具有独特的抗癌作用。而其中的鞣质及红豆杉精油中的环氧乙烷是重要的有机合成原料之一。用于制造乙二醇、合成洗涤剂、乳化剂、非离子型表面活性剂、抗冻剂、增塑剂、润滑剂、杀虫剂以及用作仓库熏蒸剂。
环氧乙烷是广谱、高效的气体杀菌消毒剂。对消毒物品的穿透力强，可达到物品深部，可以杀灭数病原微生物，包括细菌繁殖体、芽孢、病毒和真菌。在医学消毒和工业灭菌上用途广泛。常用于食料、纺织物及其他方法不能消毒的对热不稳定的药品和外科器材等进行气体熏蒸消毒，如皮革、棉制品、化纤织物、精密仪器、生物制品、纸张、书籍、文件、某些药物、橡皮制品等等物质具有消炎的作用。
发明内容
本发明提供了一种以红豆杉精油及红豆杉提取物为原料的1、口服2、外用涂抹型通过皮肤吸收、直接作用在病灶的消炎杀菌药。
本发明所涉及的红豆杉精油是以常见的各种红豆杉的枝叶为原料，经过洗净、切碎、然后通过高温蒸馏出油水混合物，冷凝后，用分层技术得到的具有强挥发性的液体物质。
本发明所涉及的红豆杉提取物是常见的各种红豆杉的枝叶为原料，经过洗净、切碎、然后通过物理方法熬制、去渣过滤后浓缩后的物质。
用红豆杉精油及红豆杉提取物为原料的消炎杀菌药物，分为口服和外用型。红豆杉精油为原料的消炎杀菌药口服的剂型分别为：混悬剂、胶囊剂、乳状剂等。外用型分为泡沫剂、乳状剂和混悬剂。以红豆杉提取物为原料的消炎杀菌药口服的剂型分别为：胶囊剂、片剂、混悬剂、乳状剂，外用剂型分为栓剂、粉末剂、泡沫剂、乳状剂、混悬剂等。
具体实施方式
本红豆杉精油及红豆杉提取物为原料的消炎杀菌药品的给药实施方法1是：口服消炎药物，制成混悬剂、胶囊、乳状剂后，直接通过肠胃吸收利用。外用剂型制成泡沫剂、乳状剂、粉剂和混悬剂后，直接涂抹或喷洒在病灶部位，因红豆杉精油具有强烈的渗透作用，因此通过皮肤或者粘膜吸收后直接作用于病灶。 主要用于女性乳房部位及生殖系统的各种炎症，如乳腺炎、淋巴炎、阴道炎、宫颈炎、宫颈糜烂等。在上述消炎过程中，还可阻止上述部位癌变、抑制癌症的产生。
具体以双黄连做为对照物的抑菌试验结果表明：红豆杉精油及红豆杉提取物对白假丝酵母菌、肺炎克雷姆菌、大肠挨希菌、金黄色葡萄球菌均有明显的抑制和杀灭作用。
直接作用于癌细胞的实验方法与结果：
1.1药品与试剂
紫杉醇挥发油、紫杉醇提取物由公司提供。DMEM培养基，美国sigma公司；DMSO、胰蛋白酶、美国Amresco公司；胎牛血清，杭州四季青生物工程材料有限公司；其他试剂均为分析纯，北京化工厂。DMIL HC倒置相差显微镜，德国Leica公司。
1.2细胞株：HEPG2(肝癌)、BGC、A549、SK-OV-3、T-47D、HELA购于中国医学科学院基础所
2、方法
2.1分组处理
2.1.1紫杉醇挥发油的抗肿瘤作用研究
药品用无血清培养基按一定浓度配制，0.22μm微孔滤膜过滤，4℃储存备用。实验分为空白对照组，紫杉醇挥发油不同浓度处理组(1.25μL/mL、0.6μL/mL、0.5μL/mL、0.4μL/mL、0.35μL/mL、0.3μL/mL、0.15μL/mL)、阳性对照组(阿霉素10μMOL/L)；每组4孔，重复三次。
2.2细胞培养细胞用含10％胎牛血清的培养基进行培养，于对数生长期接种于96孔板，每孔100μL，细胞密度为1*105。37℃、5％CO二氧化碳培养箱中2培养24h，弃上清，每孔加入含药培养基，每孔100μL，然后继续于孵箱中培养48h。
2.3MTT法检测细胞存活率药物作用48h后，弃上清液，每孔加100μl的DMEM培养液和20μL 5mg/ml的MTT，37℃、5％CO2培养箱培养4h，弃上清液，加入DMSO 150μl，振荡10min，在570nm酶标仪下检测各孔的吸收度值(A)。按下式求得心肌细胞的存活率：存活率＝(各组细胞A/正常组细胞A)×100％。并计算药物的IC50。
2.4统计学处理
实验结果采用SPSS10.0进行统计学处理。
3、实验结果：
3.1红豆杉精油对HEPG2、T-47D、SK-OV-3三种细胞的抑制率呈明显的量效关系， 其IC50为0.44、0.55、0.381μL/ml。
3.2、红豆杉精油对Hela、BGC、A549三种细胞的抑制率呈明显的量效关系，其IC50为0.595、0.587、0.526μL/ml。
本红豆杉精油及红豆杉提取物为原料消炎杀菌药品的有益效果是：
通过日常对女性生殖系统和乳腺系统炎症的治疗的同时，还可以抑制、抵抗女性上述部位癌症的发生，有效地阻止了女性生殖系统和乳腺系统由炎症到癌症的转变。
Claims (10)
1.一种具有消炎及预防癌症双重功效的药物，以红豆杉枝叶提取的红豆杉精油及提取物为原料，制成口服的混悬剂、胶囊、乳状剂后，直接通过肠胃吸收利用用于治疗炎症；以及制成泡沫剂、乳状剂、粉剂和混悬剂后直接涂抹或喷洒在病灶部位.利用红豆杉精油具有强烈的渗透作用，通过皮肤或者粘膜吸收后直接作用于病灶，外用主要用于治疗女性乳房部位及生殖系统的各种炎症，如乳腺炎、淋巴炎、阴道炎、宫颈炎、宫颈糜烂等。在上述消炎过程中，还可阻止上述部位癌变、抑制癌症的产生。
2.根据权利要求1中所述的消炎药，其特征是利用A、红豆杉科红豆杉属的各品种的枝叶，用物理提取的方法，通过高温蒸馏而得的具有强烈挥发性的物质，即红豆杉精油，以及B、通过物理方法熬制、过滤、浓缩所取得的红豆杉提取物作为主要原料，根据不同的剂型配以其它的物质而成的。
3.根据权利要求1中所述的消炎药，主要的给药方式有两种：口服和外用。口服通过肠胃吸收而达到利用目的，外用为局部给药，-通过皮肤和粘膜吸收而直接作用于病灶，用于治疗女性乳房部位及生殖系统的各种炎症，如乳腺炎、淋巴炎、阴道炎、宫颈炎、宫颈糜烂等
4.根据权利要求1中所述的消炎药，其特征是不但可以消除女性的生殖系统和乳癌系统各种炎症，还在消除炎症的同时预防女性上述部位癌症的发生，达到阻止女性上述部位由炎症向癌症的转变的目的。
5.以红豆杉精油和红豆杉提取物为主要原料的消炎药，剂型分为混悬剂、胶囊剂、乳剂、粉剂和泡沫剂。根据口服和外用的不同给药方式而分为不同的剂型和不同的配比比例。
6.根据权利要求5所述的消炎药，泡沫剂主要通过物理方式，在喷射的过程中使药物变成泡沫状，用于直接喷射到女性阴道或子宫、宫颈等较隐秘的部位，对女性的上述部位炎症进行局部给药，直接作用于病灶。
7.根据权利要求5所述的消炎药，混悬剂是把红豆杉精油或红豆杉提取物融入其他可食用的植物油或液体内，制成混悬剂，口服或者外用。根据给药方式的不同而配比的比例不同。
8.根据权利要求5所述的消炎药，胶囊剂是把红豆杉精油融入其他可食用的植物油后，用食用明胶包裹，口服给药用。或者把红豆杉提取物直接包裹在明胶内，口服给药用。
9.根据权利要求5所述的消炎药，乳剂是把红豆杉精油或红豆杉提取物融入其他物质，口服或者外用给药，根据给药方式不同而融入不同的物质。
10.根据权利要求5所述的消炎药，粉剂是把红豆杉提取物烘干，磨成500目以上的粉状物，直接喷于患处，进行局部外用给药。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100946039A CN102178704A (zh) | 2011-04-15 | 2011-04-15 | 以红豆杉精油和红豆杉提取物为原料的消炎药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100946039A CN102178704A (zh) | 2011-04-15 | 2011-04-15 | 以红豆杉精油和红豆杉提取物为原料的消炎药 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102178704A true CN102178704A (zh) | 2011-09-14 |
Family
ID=44565110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100946039A Pending CN102178704A (zh) | 2011-04-15 | 2011-04-15 | 以红豆杉精油和红豆杉提取物为原料的消炎药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102178704A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335454A (zh) * | 2011-09-29 | 2012-02-01 | 胡红节 | 一种含红豆杉的卫生巾、卫生纸或护翼及制造方法 |
| CN103285082A (zh) * | 2013-06-13 | 2013-09-11 | 江苏红豆杉药业有限公司 | 一种用于治疗妇科炎症的药物组合物 |
| CN104257601A (zh) * | 2014-07-30 | 2015-01-07 | 上海和森生物科技有限公司 | 酸性超氧化物歧化酶凝胶的制备方法 |
| CN104324363A (zh) * | 2014-09-30 | 2015-02-04 | 苑振贵 | 一种治疗宫颈糜烂和宫颈癌的药物 |
| CN107737289A (zh) * | 2017-12-02 | 2018-02-27 | 詹勇 | 一种高泡组合物产品及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101104007A (zh) * | 2007-06-07 | 2008-01-16 | 甘肃绿莹环境技术工程有限公司 | 紫杉叶在制备治疗咽喉炎药液中的应用 |
| CN101254217A (zh) * | 2008-04-14 | 2008-09-03 | 梅州市中大南药发展有限公司 | 一种红豆杉树可再生部分的提取物的制备方法及该提取物在制备口服抗癌药物中的应用 |
| CN101991516A (zh) * | 2009-08-14 | 2011-03-30 | 杨骅力 | 红豆杉精油及红豆杉萃取物为原料的保健型化妆品 |
-
2011
- 2011-04-15 CN CN2011100946039A patent/CN102178704A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101104007A (zh) * | 2007-06-07 | 2008-01-16 | 甘肃绿莹环境技术工程有限公司 | 紫杉叶在制备治疗咽喉炎药液中的应用 |
| CN101254217A (zh) * | 2008-04-14 | 2008-09-03 | 梅州市中大南药发展有限公司 | 一种红豆杉树可再生部分的提取物的制备方法及该提取物在制备口服抗癌药物中的应用 |
| CN101991516A (zh) * | 2009-08-14 | 2011-03-30 | 杨骅力 | 红豆杉精油及红豆杉萃取物为原料的保健型化妆品 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335454A (zh) * | 2011-09-29 | 2012-02-01 | 胡红节 | 一种含红豆杉的卫生巾、卫生纸或护翼及制造方法 |
| CN103285082A (zh) * | 2013-06-13 | 2013-09-11 | 江苏红豆杉药业有限公司 | 一种用于治疗妇科炎症的药物组合物 |
| CN104257601A (zh) * | 2014-07-30 | 2015-01-07 | 上海和森生物科技有限公司 | 酸性超氧化物歧化酶凝胶的制备方法 |
| CN104324363A (zh) * | 2014-09-30 | 2015-02-04 | 苑振贵 | 一种治疗宫颈糜烂和宫颈癌的药物 |
| CN107737289A (zh) * | 2017-12-02 | 2018-02-27 | 詹勇 | 一种高泡组合物产品及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paliya et al. | The genus Usnea: A potent phytomedicine with multifarious ethnobotany, phytochemistry and pharmacology | |
| Liu et al. | Optimization, chemical constituents and bioactivity of essential oil from Iberis amara seeds extracted by ultrasound-assisted hydro-distillation compared to conventional techniques | |
| Lourens et al. | South African Helichrysum species: a review of the traditional uses, biological activity and phytochemistry | |
| CN101940224B (zh) | 植物抑菌组合物及其用途 | |
| CN102178704A (zh) | 以红豆杉精油和红豆杉提取物为原料的消炎药 | |
| Kosanić et al. | Extracts of five Cladonia lichens as sources of biologically active compounds | |
| Adenubi et al. | Lichens: An update on their ethnopharmacological uses and potential as sources of drug leads | |
| Barrio et al. | Antiviral activity of Ageratina havanensis and major chemical compounds from the most active fraction | |
| EP2881113B1 (en) | New application of pogostone | |
| Alajmi et al. | Comparative anticancer and antimicrobial activity of aerial parts of Acacia salicina, Acacia laeta, Acacia hamulosa and Acacia tortilis grown in Saudi Arabia | |
| CN102973608A (zh) | 蟑螂提取物有效部位用于制备抑制真菌生长药物的用途 | |
| Eskandani et al. | Novel natural agents from Lamiaceae family: An evaluation on toxicity and enzyme inhibitory potential linked to diabetes mellitus | |
| Pasdaran et al. | Natural products as source of new antimicrobial compounds for skin infections | |
| Hong et al. | Chemical composition, anticancer activities and related mechanisms of the essential oil from Alpinia coriandriodora rhizome | |
| Ikbal et al. | Health benefits of green tea: A mini review | |
| Gouda et al. | Cytotoxic and antimicrobial activities of some compositae plants growing in Taif area, Saudi Arabia | |
| CN102716407A (zh) | 草果油在制备具有抑制或者杀灭白色念珠菌作用的药物中的用途 | |
| CN103054969B (zh) | 一种复合皮肤消毒剂及其制备方法 | |
| CN102219772A (zh) | 具有生物活性的土槿皮酸复合物及其制备方法 | |
| CN102265906A (zh) | 黑沙蒿杀菌剂及其制备方法 | |
| CN113633685B (zh) | 一种具有抑菌活性的中药组合物及应用 | |
| CN107822992A (zh) | 一种防治产褥感染的女性护理湿巾 | |
| CN104825744A (zh) | 一种治疗阴道炎的中药凝胶剂及其制备方法和应用 | |
| CN102641314A (zh) | 一种预防和/或治疗妇科疾病的药物组合物 | |
| CN102178705A (zh) | 以红豆杉精油为主要原料的抗癌药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: JINZHAI NATURE HEALTH TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ANHUI TIANMA TACUS TECHNOLOGY CO., LTD. Effective date: 20141114 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20141114 Address after: 237343 Anhui city of Lu'an province Jinzhai County Horse Village fan heart group Zhaizhen paradise Applicant after: Yang Huali Applicant after: Jinzhai County Health Science and Technology Co., Ltd. Address before: 237343 Anhui province Jinzhai County Zhai Zhen Ma Shi Cun fan group heart heaven Applicant before: Yang Huali Applicant before: Anhui Tianma Tacus Technology Co., Ltd. |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110914 |